Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis
Clinical and Experimental Medicine · 09.01.2025 · 25 (1)
DOI: 10.1007/s10238-024-01540-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Medicine, online erschienen am 09.01.2025. Verfasst von Youssef M Hassan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Zoology, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt. Hauptthemen laut MEDLINE: CRISPR-Cas Systems, Molecular Diagnostic Techniques, Point-of-Care Testing. Die Arbeit wurde bisher 137-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ain Shams University.
Abstract (Originalsprache)
The demand for sensitive, rapid, and affordable diagnostic techniques has surged, particularly following the COVID-19 pandemic, driving the development of CRISPR-based diagnostic tools that utilize Cas effector proteins (such as Cas9, Cas12, and Cas13) as viable alternatives to traditional nucleic acid-based detection methods. These CRISPR systems, often integrated with biosensing and amplification technologies, provide precise, rapid, and portable diagnostics, making on-site testing without the need for extensive infrastructure feasible, especially in underserved or rural areas. In contrast, traditional diagnostic methods, while still essential, are often limited by the need for costly equipment and skilled operators, restricting their accessibility. As a result, developing accessible, user-friendly solutions for at-home, field, and laboratory diagnostics has become a key focus in CRISPR diagnostic innovations. This review examines the current state of CRISPR-based diagnostics and their potential applications across a wide range of diseases, including cancers (e.g., colorectal and breast cancer), genetic disorders (e.g., sickle cell disease), and infectious diseases (e.g., tuberculosis, malaria, Zika virus, and human papillomavirus). Additionally, the integration of machine learning (ML) and artificial intelligence (AI) to enhance the accuracy, scalability, and efficiency of CRISPR diagnostics is discussed, alongside the challenges of incorporating CRISPR technologies into point-of-care settings. The review also explores the potential for these cutting-edge tools to revolutionize disease diagnosis and personalized treatment in the future, while identifying the challenges and future directions necessary to address existing gaps in CRISPR-based diagnostic research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Zoology, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt.
- Biotechnology Program, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt.
- Department of Zoology, Faculty of Science, Ain Shams University, Abbassia, Cairo, 11566, Egypt. wael_farag@sci.asu.edu.eg.
Förderung
- Ain Shams University
Zitieren
APA
Hassan, Y. M., Mohamed, A. S., Hassan, Y. M., & El-Sayed, W. M. (2025). Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis. Clinical and Experimental Medicine, 25(1). https://doi.org/10.1007/s10238-024-01540-8
Vancouver
Hassan YM, Mohamed AS, Hassan YM, El-Sayed WM. Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis. Clinical and Experimental Medicine. 2025;25(1). doi:10.1007/s10238-024-01540-8
BibTeX
@article{Hassan2025,
author = {Hassan, Youssef M and Mohamed, Ahmed S and Hassan, Yaser M and El-Sayed, Wael M},
title = {Recent developments and future directions in point-of-care next-generation CRISPR-based rapid diagnosis},
journal = {Clinical and Experimental Medicine},
year = {2025},
volume = {25},
number = {1},
doi = {10.1007/s10238-024-01540-8}
}
EUVIMED